Tech Sector Index (NDXX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

These caterpillars carry a toxic chemical cocktail and Inquisition-like delivery implements—and their geographic range is ...

But, as this special report snapshot shows, a host of new trials and targeted therapeutics are beginning to show serious dividends.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX – Research Report), Amgen (AMGN – ...

ASX rises despite Wall Street dip, Alibaba’s AI shakes Nvidia, Lovisa hit with class action and IGO posts quarterly earnings ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...